Catalog No.
DHD37503
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20138
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
SGN-CD33A, h2H12ec-SGD-1910, h2H12ec-mc-val-ala-SGD-1882, CAS: 1436390-63-4
Clone ID
Vadastuximab
Investigational CD33-targeted therapeutics for acute myeloid leukemia, PMID: 29534618
CD33-Targeted Therapies: Beating the Disease or Beaten to Death?, PMID: 32875599
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML, PMID: 30045838
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia, PMID: 29196412
Emerging therapies for acute myeloid leukemia, PMID: 28420416
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy, PMID: 32543981
ADCs Show Promise in Leukemias, PMID: 27388473
How can one optimize induction therapy in AML?, PMID: 29156199
CD33-Targeted Therapies: Beating the Disease or Beaten to Death?, PMID:32875599
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy., PMID:32543981
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML., PMID:30045838
Investigational CD33-targeted therapeutics for acute myeloid leukemia., PMID:29534618
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia., PMID:29196412
How can one optimize induction therapy in AML?, PMID:29156199
Emerging therapies for acute myeloid leukemia., PMID:28420416
ADCs Show Promise in Leukemias., PMID:27388473
For research use only. Not for human or drug use.
